Casgevy has demonstrated that scientists can use gene editing to treat inherited diseases. Yet several programmes that once appeared close behind have struggled to reach patients. Their stories reveal a deeper challenge facing modern medicine: changing human DNA may be becoming possible, but turning that ability into a safe, practical and affordable treatment remains a much harder task.

Curator’s note: Scientific discovery often moves faster than our ability to use it wisely. The story of CRISPR reveals the distance between understanding how to change biological systems and building treatments patients can safely receive, afford and benefit from throughout their lives.

Introduction: The Extraordinary Distance Between Discovery and Reality

There is something remarkable about the idea that a disease inherited through generations might one day be treated by changing the genetic instructions responsible for it. For much of modern medical history, doctors have focused on managing the consequences of genetic disorders. They have developed medicines to control symptoms, procedures to reduce complications and treatments that help patients live longer with conditions that cannot easily be corrected at their source. Gene editing introduced a different possibility. What if medicine could reach the underlying genetic instructions and change the biological process responsible for the disease?

This possibility gave CRISPR an unusual place in scientific research. It was no longer simply another laboratory technique. It represented a different way of thinking about disease, treatment and the relationship between human biology and technology. Scientists could now direct molecular tools towards particular DNA sequences and make targeted changes with a level of flexibility that had previously been difficult to achieve. The implications were enormous, especially for inherited diseases in which a relatively small genetic change can have lifelong consequences.

The excitement was not based entirely on speculation. In December 2023, the US Food and Drug Administration approved Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease. It became the first FDA-approved medicine using CRISPR-Cas9 technology. The United Kingdom had already granted conditional approval in November 2023. A scientific approach that had once existed primarily in research laboratories had crossed an important boundary and become a real treatment option.

But the development of CRISPR medicines has not followed the straightforward path many people expected. Editas Medicine announced in December 2024 that it was ending development of reni-cel after failing to secure a commercial partner. Novartis had discontinued its OTQ923 programme in February 2023, even though early clinical research had demonstrated increased fetal haemoglobin in treated patients. Other companies have also changed their research priorities, reduced their programmes or shifted towards different approaches to delivering gene-editing technology.

These developments create a question that deserves much more attention than simply asking which companies have succeeded and which have failed. If CRISPR has already produced an approved medicine, why have other programmes struggled to reach the same destination? Why can a treatment demonstrate promising biological activity in human patients and still lose its commercial future? And why does the ability to modify DNA remain so difficult to translate into medicines that can be manufactured reliably, administered safely and made accessible to large patient populations?

The answers extend beyond molecular biology. They involve clinical evidence, manufacturing, financial sustainability, regulatory expectations, healthcare infrastructure and the decisions companies make when several promising scientific opportunities compete for limited resources.

There is also a more fundamental issue beneath these developments. Scientific discovery and practical progress are often treated as if they are the same thing. Yet discovering that something can be done does not automatically establish that it can be done consistently, safely or at a scale that benefits society. A successful experiment may demonstrate a possibility without providing a complete solution to the problem that inspired it.

The history of CRISPR medicines offers a particularly clear example of this distinction. Casgevy has demonstrated what gene editing can achieve. The programmes that have been discontinued reveal what still stands between that achievement and a much broader medical transformation.

Casgevy: The Breakthrough That Changed the Possibilities of Medicine

Casgevy became a landmark because it demonstrated that CRISPR could produce a meaningful clinical benefit in people living with serious inherited blood disorders. Its approvals cover sickle cell disease and transfusion-dependent beta-thalassaemia, two conditions that can place an enormous burden on patients throughout their lives.

Sickle cell disease is caused by a mutation in the HBB gene, which leads to the production of abnormal haemoglobin. Under certain conditions, this haemoglobin causes red blood cells to become rigid and sickle-shaped. These cells can obstruct small blood vessels, interrupt normal blood flow and trigger painful vaso-occlusive crises. Repeated episodes can contribute to organ damage, chronic anaemia and other serious complications. For many patients, the disease involves repeated hospital admissions and a lifetime of medical management.

Beta-thalassaemia involves a different problem. The body cannot produce sufficient functional beta-globin, a component required to form adult haemoglobin. Patients with severe forms of the condition may require regular blood transfusions, sometimes every few weeks, along with treatment to manage excess iron accumulating in the body.

Casgevy approaches these diseases through a biological pathway that is already present in the human body. Rather than directly correcting the original genetic mutations, it aims to increase the production of fetal haemoglobin. This form of haemoglobin is naturally produced before birth and has the ability to carry oxygen without being affected by the sickling process in the same way as adult sickle haemoglobin.

During normal development, fetal haemoglobin production decreases after birth as adult haemoglobin becomes dominant. Researchers discovered that increasing fetal haemoglobin in adults could reduce the harmful effects of sickle haemoglobin and improve the symptoms associated with sickle cell disease.

Casgevy uses CRISPR-Cas9 to modify an erythroid-specific regulatory region of the BCL11A gene in a patient’s blood stem cells. BCL11A normally contributes to the suppression of fetal haemoglobin production. By disrupting its activity in developing red blood cells, the treatment allows fetal haemoglobin levels to increase.

The approach is scientifically interesting because it does not require repairing every defective copy of the original haemoglobin gene. Instead, it changes another part of the biological system to reduce the consequences of the disease.

The clinical findings were encouraging. In the pivotal sickle cell disease trial, 29 of 31 evaluable patients, representing approximately 93.5%, experienced freedom from severe vaso-occlusive crises for at least twelve consecutive months. All 30 evaluable patients achieved the specified period without hospitalisation for severe vaso-occlusive crises.

These outcomes represented a significant change in what treatment could offer. For someone who has spent years living with unpredictable episodes of severe pain, a prolonged period without such crises can mean greater independence and a more predictable daily life.

The treatment also demonstrated that edited stem cells could engraft and continue producing blood cells with increased fetal haemoglobin. This is important because the purpose of gene editing is to produce a lasting biological effect rather than a temporary improvement that disappears when treatment stops.

Casgevy’s regulatory progress has continued beyond its original approvals. On July 1, 2026, the FDA expanded its approval to include children as young as two years old with sickle cell disease or transfusion-dependent beta-thalassaemia. This made it the first genetic therapy approved in the United States for children as young as two with sickle cell disease. The FDA’s decision also reflected the growing clinical experience supporting the treatment, although long-term monitoring remains essential.

Its commercial progress has become more visible as well. According to Vertex Pharmaceuticals’ third-quarter 2026 financial results, Casgevy generated $99 million in revenue during the quarter, representing approximately 30% growth compared with the previous quarter and nearly six times the revenue recorded during the same period in 2025. This suggests that commercial adoption is accelerating.

However, the treatment numbers also reveal the distance between regulatory approval and widespread medical access. During 2025, 64 patients received Casgevy infusions, while 147 patients globally completed their first cell collection. By the end of that year, approximately 90% of eligible patients in the United States had reimbursed access to the treatment, according to Vertex. Yet reimbursement does not necessarily mean that every eligible patient can immediately complete the treatment process.

Casgevy has therefore established something important, but it has not solved every problem surrounding gene-editing medicines. Its success demonstrates that a particular genetic intervention can produce meaningful clinical benefits under carefully controlled conditions. It does not establish that every promising CRISPR programme can follow the same path.

The difference between proving a technology and building an entire medical system around it is where the next part of this story begins.

Reni-cel: When Promising Clinical Results Are Not Enough

The discontinuation of reni-cel by Editas Medicine illustrates how a treatment can demonstrate encouraging scientific potential without securing the resources needed to continue its development.

Previously known as EDIT-301, reni-cel was developed for sickle cell disease and transfusion-dependent beta-thalassaemia. Its scientific approach shared an important objective with Casgevy: increasing fetal haemoglobin to reduce the harmful effects of abnormal adult haemoglobin.

However, the two treatments used different editing strategies. Casgevy targets an erythroid-specific regulatory region of BCL11A using CRISPR-Cas9. Reni-cel used CRISPR-Cas12a to modify promoter regions associated with the HBG1 and HBG2 genes, which encode the gamma-globin chains that form fetal haemoglobin.

The reasoning behind reni-cel was straightforward. If researchers could directly modify the regulatory regions controlling fetal haemoglobin production, they might be able to reactivate this protective form of haemoglobin and reduce the effects of sickle cell disease.

The programme advanced through the RUBY clinical trial for sickle cell disease and the EdiTHAL trial for transfusion-dependent beta-thalassaemia. Early findings showed that the treatment could increase fetal haemoglobin and produce encouraging clinical activity. These findings suggested that the underlying biological approach was worth investigating further.

Then, on December 12, 2024, Editas announced that it was ending reni-cel development.

The company’s explanation was revealing. After an extensive search, it had failed to secure a commercial partner willing to support the programme’s further development. Editas decided to redirect its resources towards in vivo gene-editing technologies, which aim to modify genetic material directly inside the body.

The decision was accompanied by a broader restructuring. Editas announced an approximately 65% reduction in its workforce, representing around 180 positions, as it redirected its resources towards its in vivo research pipeline. Its 2024 financial results reported a net loss of approximately $237.1 million, illustrating the financial pressure facing the company. The discontinuation and associated restructuring also involved substantial costs.

The decision exposes an uncomfortable reality of biotechnology research. A promising treatment does not necessarily have an independent future simply because the underlying science is encouraging.

Developing a medicine requires sustained financial support. Clinical trials must continue, manufacturing processes must be validated, regulatory requirements must be met and commercial infrastructure must be established. A company must be able to finance all of this while accepting that further studies may reveal problems that were not apparent in earlier research.

For a smaller biotechnology company, the burden can become particularly difficult.

An experimental treatment may have reached a stage where the next clinical trial requires substantially more capital than the company can reasonably provide. A pharmaceutical partner can help by contributing financial resources, manufacturing expertise, regulatory experience and access to commercial distribution networks.

Without such a partner, the company may face a choice between investing heavily in one programme or redirecting its limited resources towards a different technology that it believes offers greater long-term potential.

Reni-cel demonstrates how such a decision can shape the future of a scientific discovery.

Its discontinuation should not be interpreted as proof that the underlying editing strategy was ineffective. It should also not be described as a successful medicine that was merely prevented from reaching patients. The available evidence had not established the long-term efficacy and safety required for approval.

The more accurate interpretation is that reni-cel showed encouraging early clinical potential, but its development did not secure the commercial support needed to continue.

That distinction matters because scientific evidence and commercial decisions answer different questions. One asks whether a treatment can produce a biological effect. The other asks whether an organisation is prepared and able to invest in turning that effect into an approved medicine.

OTQ923: When a Pharmaceutical Company Changes Its Direction

Novartis’s OTQ923 programme offers another perspective on the challenges facing CRISPR medicines.

Developed with Intellia Therapeutics, OTQ923 was an experimental CRISPR-Cas9 treatment for sickle cell disease. Like reni-cel, it aimed to increase fetal haemoglobin by editing regulatory regions associated with the HBG1 and HBG2 genes.

The clinical findings from OTQ923 were published in the New England Journal of Medicine in August 2023. The study involved three patients with severe sickle cell disease who received the edited cell product. All three achieved successful engraftment, and fetal haemoglobin increased substantially, accounting for approximately 19% to 26.8% of total haemoglobin. Fetal haemoglobin was also distributed across a large proportion of red blood cells.

Researchers observed improvements in disease manifestations during follow-up. However, the study was extremely small, and the results could not establish how consistently the treatment would work across a larger patient population.

An important detail about the programme’s history is often overlooked. Novartis discontinued OTQ923 in February 2023, before the publication of the clinical findings. The decision was based on strategic business considerations rather than a publicly announced clinical safety failure.

The company was reviewing its research priorities and directing resources towards other opportunities. The clinical study was subsequently terminated for business reasons.

This distinction matters because it would be inaccurate to suggest that Novartis abandoned the programme after reviewing the published results. The decision preceded their publication.

OTQ923 illustrates how large pharmaceutical companies make decisions about competing research opportunities. A company may have several scientifically promising programmes, but financial resources, specialist teams and manufacturing capacity are not unlimited.

Each programme must justify the investment required to take it through further clinical trials, regulatory review and eventual commercialisation.

A decision to discontinue one treatment may therefore reflect the relative attractiveness of other opportunities rather than a conclusion that its underlying scientific approach has no value.

The circumstances surrounding OTQ923 and reni-cel were different. Editas struggled to find a commercial partner, while Novartis made a strategic portfolio decision. Yet both programmes ultimately lost their development pathways.

Their stories demonstrate why the progress of a scientific technology cannot be measured simply by counting the number of successful experiments.

The Problem That Begins After DNA Has Been Edited

The public imagination often focuses on the editing process itself. A scientist identifies a faulty genetic sequence, directs CRISPR towards it and changes the DNA. The simplicity of that description can make the entire process sound almost effortless.

But the molecular editing event is only one part of the treatment.

Casgevy, reni-cel and OTQ923 were all based on ex vivo gene editing. This means that cells are collected from the patient, modified outside the body and returned after the necessary preparation.

The process begins with collecting blood stem cells from the patient. These cells are then transported to a specialised manufacturing facility, where the editing machinery is introduced under controlled conditions.

Once the cells have been modified, they must undergo extensive quality testing. Manufacturers need to establish that the product contains the intended cell population, meets defined quality standards and has the characteristics required for treatment.

The patient must also be prepared to receive the edited cells. In Casgevy’s case, this involves myeloablative conditioning with busulfan chemotherapy. The purpose is to clear space in the bone marrow so that the edited stem cells can engraft and begin producing new blood cells.

This is a major medical intervention in its own right.

Busulfan conditioning can cause serious side effects, including infections, low blood-cell counts and potential fertility complications. Patients require specialist monitoring and a prolonged recovery period.

The treatment journey can involve months of preparation, collection, manufacturing, hospitalisation and follow-up. Each stage requires coordination between clinical teams, laboratories, manufacturing facilities and the patient.

There is also a manufacturing challenge. Each patient’s cells are collected and processed individually. The resulting treatment is therefore personalised rather than produced as a conventional medicine in large batches.

Manufacturing must be reliable, but the process must also be repeatable across different patients and clinical settings.

If a batch does not meet the required standards, it may not be suitable for infusion. If manufacturing takes longer than expected, the patient’s treatment schedule may be affected. If the patient develops a complication during preparation, the entire process may need to be reconsidered.

The difficulty is not simply making CRISPR work once. It is making the entire treatment process work consistently for hundreds or thousands of people.

This is where scientific innovation encounters the practical limits of healthcare delivery.

A treatment may be technically successful and still remain difficult to distribute because the infrastructure required to administer it is limited. Hospitals need trained specialists, specialised laboratories, intensive-care support and the ability to manage complications.

In countries where these facilities are scarce, the challenge becomes even greater.

The future of gene editing will therefore depend partly on whether medicine can simplify the systems surrounding the technology. Improving the editing process is important, but improving the collection, manufacturing, administration and monitoring processes may be equally necessary.

Why Manufacturing Has Become a Major Scientific and Commercial Challenge

The manufacturing of gene-edited cell therapies presents a different problem from the production of conventional medicines.

A pharmaceutical company can manufacture a tablet in large batches, test its quality and distribute it through established supply chains. A personalised cell therapy requires a more complicated process because the starting material comes from the individual patient.

This creates what is known as an individualised manufacturing model.

Every patient requires a separate collection process, and each manufactured product must satisfy strict quality requirements. The production process must be carefully controlled because differences in cell quality, editing efficiency and manufacturing conditions can influence the final product.

There is also a limited supply of specialised manufacturing facilities. Building these facilities requires substantial investment, regulatory expertise and trained personnel.

The manufacturing process must be capable of maintaining cell viability throughout collection, transportation, editing, testing and delivery. The cells must remain suitable for transplantation, and the final product must meet the required specifications.

These requirements increase both the cost and complexity of treatment.

Another issue is manufacturing capacity. Even if a company receives regulatory approval, it cannot immediately treat every eligible patient. The number of patients who can receive treatment depends on the available manufacturing capacity, the number of authorised treatment centres and the ability of healthcare systems to coordinate the process.

This explains why the number of patients receiving Casgevy infusions has remained much smaller than the total eligible population.

The challenge also affects smaller biotechnology companies. A company developing a treatment must often invest in clinical research while simultaneously preparing the manufacturing infrastructure required for commercialisation.

This can create a difficult financial position. The company may need to spend substantial amounts of money before it has established whether the treatment will ultimately receive regulatory approval or attract sufficient commercial demand.

The industry therefore needs manufacturing models that can reduce cost, improve consistency and increase production capacity.

Automation, improved cell-processing technologies, standardised manufacturing systems and more efficient quality-control methods may all contribute to this transition.

However, there is no simple solution. The manufacturing process must become more efficient without compromising the quality or safety of the final treatment.

The Economics of a Medical Breakthrough

Casgevy entered the US market with a list price of approximately $2.2 million per patient. The figure attracted considerable attention, particularly because sickle cell disease affects populations that have historically experienced unequal access to healthcare.

The price is difficult to understand without considering the treatment model. Casgevy is a personalised cell therapy requiring specialised collection, editing, manufacturing, conditioning and hospital-based administration.

These activities are expensive. However, explaining the cost does not automatically make the treatment affordable.

A medicine can receive regulatory approval and still remain inaccessible to many of the people who need it.

Insurance providers must decide whether and how to cover the treatment. Healthcare systems must negotiate reimbursement arrangements. Hospitals need the infrastructure and trained personnel required to administer it. Patients may also need to travel long distances to reach authorised treatment centres.

These costs extend beyond the medicine’s list price.

Travel, accommodation, time away from employment, childcare and the practical demands of prolonged hospitalisation can create additional burdens for families.

The situation becomes particularly difficult when considering the global distribution of sickle cell disease. The condition is especially common in sub-Saharan Africa, while substantial patient populations also live in India, the Middle East and other regions.

Many of these countries face healthcare funding limitations and unequal access to specialist treatment.

A treatment that costs millions of dollars may be available in a wealthy healthcare system but remain financially unrealistic in a country where the majority of patients cannot access even consistent basic disease management.

This raises a question that deserves to be central to discussions about medical innovation: what does a scientific breakthrough mean if the people most affected by the disease cannot benefit from it?

The answer requires more than reducing the price of a single medicine.

Manufacturing processes must become more efficient. Treatment infrastructure needs to expand. Payment systems must find ways to manage high upfront costs. Companies and healthcare institutions must also consider how advanced therapies can be made available in countries with fewer resources.

There are already attempts to address this problem. In the United States, the Centers for Medicare and Medicaid Services introduced a Cell and Gene Therapy Access Model for sickle cell disease. The model aims to connect payment arrangements with treatment outcomes, creating a mechanism through which participating states can receive financial adjustments if therapies do not perform as expected.

Such approaches recognise that the traditional healthcare payment model may not be well suited to treatments involving very high upfront costs and potentially long-lasting benefits.

The economics of gene editing will require a different way of thinking about value. A treatment that costs millions initially may reduce decades of medical expenses, but this possibility must be evaluated through long-term clinical and economic evidence.

The challenge is to establish a system in which companies can recover the cost of developing innovative medicines while patients and healthcare systems are not excluded by their price.

A scientific breakthrough becomes a genuine medical achievement only when the healthcare system has a realistic way to deliver it.

The Safety Questions That Come With Permanent Genetic Changes

Gene editing introduces a particular challenge because its intended effects may be long-lasting.

Traditional medicines generally work through chemical or biological interactions that can often be reduced or stopped by changing or discontinuing treatment. Gene editing is different. Once a genetic modification has occurred in a cell, it may remain in that cell and be passed on to its descendants.

This is part of what makes gene editing attractive. A single intervention may produce a lasting therapeutic effect.

But durability also creates a higher demand for confidence.

CRISPR-Cas9 uses a guide RNA to direct the Cas9 enzyme towards a selected DNA sequence. The enzyme cuts the DNA at the intended location, and the cell’s natural repair machinery completes the process.

The system can be highly effective, but it is not infallible.

An editing tool may occasionally modify an unintended location in the genome. These events are known as off-target edits. Even when the intended location is targeted correctly, the repair process can produce unexpected changes.

Large deletions, complex rearrangements and other forms of unintended genetic alteration are important areas of investigation.

There is also the question of how edited cells behave over time.

A blood stem cell may survive and produce new generations of blood cells throughout a patient’s life. Researchers therefore need to understand not only whether the original editing event was successful, but also whether the modified cells remain stable and behave as expected over extended periods.

This is why long-term monitoring is essential.

The FDA’s prescribing information for Casgevy includes warnings concerning potential risks associated with off-target genome editing. The existence of these warnings does not mean that the treatment has been shown to cause such outcomes in patients. It reflects the need to consider risks associated with permanent genetic modification and maintain appropriate monitoring.

The balance between benefit and risk also depends on the disease being treated.

For a patient with severe sickle cell disease and repeated life-threatening complications, a treatment carrying significant short-term medical burdens may offer a meaningful potential benefit.

For a person with a condition that can be managed effectively through existing medicines, the acceptable level of risk may be considerably lower.

This distinction becomes particularly important as researchers begin exploring gene editing for conditions that are common but not necessarily immediately life-threatening.

A permanent genetic intervention to treat a serious inherited disease raises different ethical and clinical questions from a permanent intervention intended to reduce a risk factor in an otherwise healthy person.

The scientific ability to make a genetic change does not automatically establish that making it is the right medical decision.

The decision requires careful consideration of the condition, the expected benefit, the available alternatives, the patient’s circumstances and the uncertainties that remain.

In Vivo Gene Editing: Can the Next Generation Overcome Today’s Limitations?

The limitations of ex vivo treatment have encouraged researchers to explore a different approach: editing genes directly inside the body.

This is known as in vivo gene editing.

Instead of collecting cells, modifying them in a laboratory and returning them to the patient, researchers aim to deliver the editing machinery directly to the relevant tissue.

The potential advantages are considerable.

If scientists can deliver gene-editing components safely to the correct cells, they may be able to avoid much of the infrastructure required for personalised cell manufacturing. Patients might not need to undergo the same collection and manufacturing process. Some treatments could potentially be administered through an infusion, with the editing machinery travelling to the intended organ.

However, this approach introduces another major scientific problem: delivery.

CRISPR components do not automatically reach the correct cells simply because researchers know which gene they want to modify.

The editing machinery must cross biological barriers, enter the appropriate cells and reach the required intracellular location. It must also avoid causing unnecessary changes in other tissues.

Researchers are investigating several delivery methods, including lipid nanoparticles and engineered viral vectors.

Lipid nanoparticles are particularly interesting because they can carry RNA and other molecular components into cells. They have already demonstrated their value in other areas of medicine, including the delivery of mRNA-based vaccines.

The liver has become an important early target for in vivo gene editing because it naturally takes up many lipid nanoparticles circulating in the bloodstream.

This has allowed researchers to investigate treatments for diseases in which a genetic change in liver cells could produce a meaningful therapeutic effect.

Intellia Therapeutics has explored this approach through programmes such as NTLA-2001, designed to edit the TTR gene in patients with transthyretin amyloidosis. The treatment aims to reduce the production of transthyretin protein by modifying liver cells.

Early clinical research demonstrated substantial reductions in circulating transthyretin after treatment. However, the programme has also faced regulatory scrutiny concerning liver-related safety monitoring. In March 2026, the FDA lifted a clinical hold after the company aligned its trial protocol with additional monitoring and safety requirements.

This illustrates both the potential and the difficulty of in vivo editing. Delivering the editing machinery directly into the body can simplify certain parts of treatment, but it also means that researchers must understand how the components behave after administration.

A further development came from a highly personalised gene-editing treatment developed for an infant with severe carbamoyl phosphate synthetase 1 deficiency. Researchers at Children’s Hospital of Philadelphia and the University of Pennsylvania developed an individualised base-editing treatment that was administered in 2025.

Although this was not a conventional commercial CRISPR medicine, it demonstrated how quickly researchers could develop a genetic intervention for a patient with an extremely rare disease.

The treatment also revealed a possible future direction for personalised medicine. Instead of waiting for a standard treatment to become available for every rare genetic condition, researchers may eventually be able to design targeted interventions for specific mutations.

However, a treatment developed for one patient is not automatically a scalable commercial product. The scientific and regulatory challenges of producing individualised medicines remain substantial.

The next generation of gene editing will therefore need to solve several problems simultaneously. Delivery must become more precise, editing must remain sufficiently safe, manufacturing must become more efficient and clinical benefits must be established through appropriate studies.

In vivo editing may remove some of the limitations associated with ex vivo treatments, but it introduces a different set of challenges rather than eliminating complexity altogether.

The Deeper Wisdom: Knowing What We Can Do Is Not the Same as Understanding What We Should Do

The story of CRISPR becomes more interesting when viewed beyond the laboratory and the financial statements of biotechnology companies.

Human beings have an extraordinary ability to discover, examine and change the world around them. Yet the history of progress repeatedly shows that the ability to do something often develops faster than the wisdom required to use it properly.

This is not a problem unique to genetic engineering. It is a recurring feature of human knowledge.

We learn how to control a process, but we do not always understand all the consequences of controlling it. We discover a powerful tool and begin imagining its possibilities before fully examining its limitations. Sometimes our confidence grows because we have learned how to produce a particular result, even though we have not yet understood the wider system in which that result exists.

CRISPR provides a particularly powerful example.

Scientists can now modify selected genetic sequences, but the human genome does not exist as a collection of completely independent instructions. Genes interact with other genes, proteins, cells, tissues and environmental conditions. A change introduced at one point may influence processes elsewhere. Understanding the immediate result of an edit is therefore different from understanding every consequence it may produce throughout a person’s life.

This raises a question about the nature of knowledge itself. How much do we actually understand when we have learned to control only one part of a much larger system?

There is a tendency to measure intelligence through the things we can accomplish. A successful experiment, a new technology or a complicated scientific achievement becomes evidence of how far human understanding has advanced. Yet there is another dimension of intelligence that receives less attention: the ability to recognise what remains unknown.

Knowing the limits of one’s understanding is not a weakness. It is part of understanding.

In science, this recognition becomes essential because every discovery opens new questions. An editing system may successfully modify a target sequence, but researchers must still investigate unintended changes, long-term cellular behaviour, delivery limitations and the consequences of the intervention. The more powerful the technology becomes, the greater the importance of examining what it cannot yet guarantee.

There is also a difference between acquiring knowledge and using it responsibly. A person may understand how to perform an action without having considered whether the action is justified, beneficial or appropriate under the circumstances.

The same principle applies to scientific institutions.

A biotechnology company may possess the technical ability to develop a treatment, but it must also consider the risks patients will face, the financial resources required and the people who may never be able to access the resulting medicine. The commercial success of a technology does not automatically establish its social value.

A treatment priced beyond the reach of most patients may represent a major scientific achievement while leaving an enormous gap between innovation and human benefit.

This is where responsibility becomes inseparable from knowledge.

The ability to influence a biological system gives researchers and companies greater power over the conditions in which people live. That power creates an obligation to examine consequences beyond the immediate result. It requires patience, honesty and a willingness to acknowledge uncertainty, even when commercial expectations encourage faster progress.

Another important distinction concerns the way human beings interpret success.

When something works once, we can become tempted to believe that we have understood it completely. Yet a result achieved under controlled conditions does not necessarily remain predictable in a different environment. The laboratory, the clinical trial and the healthcare system are not identical settings. Each introduces new variables and new responsibilities.

This is why the discontinued CRISPR programmes deserve to be studied carefully. Their stories remind us that an encouraging result is not the end of an investigation. Sometimes it is only the beginning of a much more difficult question.

There is also a deeper issue concerning ambition.

Scientific progress is often driven by the desire to overcome limitations. This ambition has produced extraordinary benefits for humanity. But ambition becomes dangerous when the desire to achieve something begins to replace the responsibility to understand its consequences.

The difference can be subtle. A researcher may become so focused on demonstrating that an intervention works that the wider questions receive less attention. A company may become so concerned with protecting its financial position that a promising programme loses its place. A healthcare system may celebrate the approval of a treatment without examining whether the people who need it can actually receive it.

In each case, the immediate objective can become larger than the purpose that originally gave it meaning.

Perhaps one of the most important lessons of medical innovation is that the value of knowledge depends partly on the purpose for which it is used. The ability to change something does not, by itself, establish that the change will improve the world around it.

This becomes especially important when the subject is human life.

A genetic intervention is not simply a technical modification. It may influence a person’s future health, family circumstances, independence and quality of life. Decisions about such treatments must therefore consider the individual as a whole rather than reducing the patient to a genetic sequence that needs correction.

There is another dimension of this discussion that concerns fairness.

Human beings do not begin life with equal access to opportunities, resources or healthcare. A scientific breakthrough can therefore produce very different outcomes depending on the circumstances in which it is introduced. If a treatment is available only to people living near specialist hospitals or those covered by expensive insurance systems, its benefits will naturally be distributed unequally.

The challenge is not merely to create something valuable. It is to consider who will be able to benefit from it.

This is a question of justice as much as economics.

Scientific institutions often discuss innovation through the language of intellectual property, commercial partnerships, market opportunities and technological leadership. These considerations are legitimate, but they should not make us forget the human purpose behind medical research.

The original reason for developing treatments for sickle cell disease was that people were suffering from a condition that affected almost every part of their lives. The technology was developed to reduce that suffering. If the resulting medicine becomes so complicated or expensive that only a limited number of people can receive it, then an important part of the original objective remains unfinished.

The same principle applies to the way researchers deal with uncertainty.

There is no shame in acknowledging that a treatment has limitations. In fact, honest recognition of uncertainty is one of the foundations of reliable scientific progress. The problem begins when the desire to appear successful becomes stronger than the willingness to examine what remains unresolved.

An experiment that produces an unexpected result can still contribute to knowledge. A discontinued programme can still teach researchers something valuable. A treatment that does not reach commercial development may still reveal biological mechanisms that help future discoveries.

The value of an investigation should therefore not be measured only by whether it becomes a profitable product.

At the same time, good intentions cannot replace evidence. A treatment should not be considered safe simply because its purpose is noble. Its effectiveness must be demonstrated, its risks must be understood as far as possible and its benefits must justify the intervention.

Wisdom requires both ambition and restraint. It allows people to pursue difficult discoveries without becoming so attached to their expectations that they stop examining reality.

This is perhaps the most important lesson hidden within the development of CRISPR medicines. Humanity has become increasingly capable of changing the systems on which life depends. The question now is whether our judgment, responsibility and understanding can develop at the same pace as our technical abilities.

The Future of CRISPR Will Depend on More Than Better Editing Tools

The future of gene-editing medicines will depend on whether researchers can solve the practical problems that have limited the first generation of treatments.

One important area will be improving delivery. In vivo gene editing has the potential to reduce the manufacturing complexity associated with ex vivo treatments, but the editing machinery must reach the correct cells with sufficient efficiency and an acceptable safety profile.

Lipid nanoparticles, engineered viral vectors and emerging delivery systems may expand the range of tissues that can be targeted. However, liver delivery is considerably more established than delivery to many other organs. Reaching the brain, muscles, lungs and other tissues introduces additional biological barriers.

Another important development will be the expansion of editing technologies beyond conventional CRISPR-Cas9.

Base editing allows researchers to change individual DNA letters without introducing the same type of double-strand break used by conventional CRISPR-Cas9 editing. Prime editing offers another approach, using a modified Cas enzyme and a specialised RNA template to introduce more varied genetic changes.

These technologies may eventually address mutations that cannot be treated effectively through existing editing strategies.

However, newer editing methods are not automatically safer or more effective. Each technology introduces its own delivery, efficiency, manufacturing and safety questions. Their clinical value will need to be demonstrated through careful research.

The financial structure of gene-editing development will also need to change.

Smaller biotechnology companies often develop innovative technologies but lack the resources required to complete expensive clinical programmes. Partnerships with pharmaceutical companies can help bridge this gap, but commercial interest can shift as companies change their priorities.

The experience of reni-cel shows that scientific promise alone may not be sufficient to attract the necessary investment.

More sustainable financing models, research collaborations and manufacturing partnerships may help prevent promising programmes from becoming dependent on a single company’s financial position.

Healthcare systems will also need to prepare for treatments that involve substantial upfront costs but may provide long-term benefits.

Payment arrangements based on outcomes could become more important. Under such models, manufacturers and healthcare providers may share some of the financial uncertainty associated with treatment effectiveness.

However, these arrangements will only work if clinical outcomes can be measured reliably and patients can be monitored over sufficiently long periods.

Accessibility will remain one of the most important tests.

Sickle cell disease affects millions of people worldwide, particularly in regions where access to specialist healthcare is limited. The development of advanced therapies in wealthy countries cannot be considered a complete solution if patients in other parts of the world remain unable to receive them.

This will require investment in healthcare infrastructure, specialist training, local manufacturing capabilities and international cooperation.

The future of gene editing will therefore be shaped by several systems working together. Molecular biology must improve, but manufacturing, financing, regulation and healthcare delivery must improve alongside it.

The next major breakthrough may not necessarily be a more powerful editing enzyme. It may be a better way of delivering an existing technology, reducing manufacturing costs or making treatment available to patients who currently have no realistic access to it.

That possibility deserves as much attention as the next scientific discovery.

Conclusion: Changing DNA Is Only the Beginning

The history of CRISPR medicines has reached an interesting stage. The technology has moved beyond theoretical promise, and Casgevy has demonstrated that editing human genes can produce meaningful clinical benefits. Yet the discontinuation of reni-cel and OTQ923 shows that the journey from scientific possibility to medical availability remains uncertain.

These programmes did not disappear for identical reasons. Reni-cel lost its development pathway after Editas failed to secure a commercial partner. Novartis discontinued OTQ923 as part of a strategic business decision. Their clinical findings were limited and required further investigation, but neither programme should simply be described as proof that CRISPR itself had failed.

Their stories reveal a broader problem. A treatment must succeed across several different environments before it can become a dependable medicine. It must work biologically, demonstrate acceptable safety, survive clinical development, meet regulatory requirements, be manufactured consistently and fit within a financial system capable of delivering it to patients.

Casgevy has crossed many of these boundaries, but even its commercial progress shows how difficult widespread access can be.

The next generation of gene-editing technologies may reduce some of these limitations. In vivo editing, base editing, prime editing and improved delivery systems offer new possibilities. Yet each will have to prove its value through careful clinical evidence rather than scientific excitement alone.

Perhaps the most important question facing the field is no longer whether humanity can change the genetic instructions responsible for disease. We have already demonstrated that this is possible in certain settings.

The more difficult question is whether we can develop the judgment, infrastructure and responsibility required to use this ability well.

A genetic breakthrough becomes meaningful when it changes the life of someone who needs it. Until that happens consistently, the distance between scientific achievement and medical progress will remain.

And perhaps that is where the future of CRISPR will ultimately be decided: not by how much of the human genome we learn to edit, but by how wisely we turn that knowledge into something that improves human life.